NeurologyLive

01/10/2026

🎧 New Mind Moments® Podcast Episode Is Live!

Episode 158 dives into bexicaserin, the PACIFIC trial, and treating developmental epileptic encephalopathies (DEEs) with guest Johannes Streffer MD, PhD, of Lundbeck.

🧠 Highlights include:
🔹 Phase 1/2 PACIFIC trial findings
🔹 Sustained reductions in motor seizures
🔹 Safety considerations in complex DEE populations
🔹 Challenges of trial design in rare pediatric epilepsy

A must-listen for anyone following advances in epilepsy and rare neurological disorders: https://hubs.li/Q03-b-Cq0

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Johannes Streffer, MD. [LISTEN TIME: 14 minutes]

01/10/2026

🚨 Promising News in Epilepsy Research 🚨

Bright Mind Biosciences announced positive Phase 2 results for BMB-101, an investigational therapy for drug-resistant absence seizures and developmental epileptic encephalopathies (DEEs).

🔹 73% median reduction in absence seizures
🔹 63% median reduction in major motor seizures
🔹 Favorable safety profile
🔹 ~90% increase in REM sleep without reducing total sleep time

Based on these results, the company plans to advance BMB-101 into a global registrational trial, offering new hope for patients with difficult-to-treat seizure disorders.

➡️ A new Phase 2a study is also underway in Prader-Willi syndrome. Read more: https://hubs.li/Q03-9FQC0

Bright Mind Biosciences reveals promising results for BMB-101 in treating drug-resistant seizures, paving the way for future clinical trials.

01/09/2026

📈🧠 Real-world data in Lennox-Gastaut syndrome

A first-of-its-kind retrospective analysis evaluated real-world persistence of fenfluramine in patients with Lennox-Gastaut syndrome using Komodo U.S. claims data. The study found that 61% of patients continued treatment at 12 months and identified trends related to ongoing use. American Epilepsy Society University of Pittsburgh

Explore the full analysis and methodology: https://hubs.li/Q03-5D_G0

01/09/2026

📌 Conference Research Highlight | AES 2025

Data presented at the 2025 American Epilepsy Society Annual Meeting reported long-term safety findings from a combined open-label extension study evaluating fenfluramine in pediatric and adult patients with Dravet syndrome and Lennox-Gastaut syndrome. Ruber Internacional

According to the analysis, safety outcomes were consistent with prior studies, and most patients demonstrated stable or improved global functioning over follow-up periods of up to 4 years.

📄 Read the full article for additional context on the study and results: https://hubs.li/Q03-5CBW0

01/09/2026

🧠📊 New Research in Lennox-Gastaut Syndrome

A post-hoc analysis from a phase 3 study and its open-label extension examined the effects of fenfluramine on everyday executive functioning in adults with Lennox-Gastaut syndrome. Findings suggested improvements in executive functioning that did not strongly correlate with reductions in fall-associated seizures, indicating these outcomes may be partly independent.

American Epilepsy Society Children’s Hospital Colorado

Read more about the study findings and their clinical context: 🔗 https://hubs.li/Q03-5w8Z0

01/08/2026

🧠 Looking Ahead: Neurology Conferences in 2026

NeurologyLive® will be covering major neurology conferences in 2026, featuring the latest advances in Alzheimer’s, multiple sclerosis, epilepsy, neuromuscular diseases, and more.

Hear from top experts, explore new therapies, and stay up to date on breakthroughs in patient care, AI applications, and gene therapy. Key events include AAIC, AAN, ACTRIMS, CMSC, MDA, MDS, AES, CNS, and PNS meetings.

Don’t miss our coverage of the research and innovations shaping the future of neurological care!

🔗 👉 https://hubs.li/Q03-6jNn0

Follow NeurologyLive's conference journey in 2026, highlighting advancements in diagnostics, treatments, and multidisciplinary care across multiple neurological conditions.

01/08/2026

⏰ 6 days to go

Neurology clinicians—join us on January 14 for the NeurologyLive® Clinical Forum, featuring an expert-led discussion on Anti-CD20 therapy use in multiple sclerosis.

This live forum will explore real-world considerations around patient selection, treatment utilization, and clinical decision-making in MS care.

👉 Save your spot: https://hubs.li/Q03-43h20

01/08/2026

🧠💊 New epilepsy research highlights benefits beyond seizure control.
Fenfluramine treatment led to long-term improvements in everyday executive functioning in adults with Lennox-Gastaut syndrome—independent of seizure reduction.

📊 Patients also showed meaningful reductions in drop seizures and were frequently rated as much improved by clinicians and caregivers.

Read more about the study and its real-world impact: https://hubs.ly/Q03-1jDq0

A recent analysis reveals fenfluramine's positive effects on executive functioning in adults with Lennox-Gastaut syndrome, independent of seizure reduction.

01/08/2026

Could a GLP-1 medication used for diabetes and weight loss help some stroke patients? 🧠

A 🆕 clinical trial found that semaglutide did not improve overall recovery after large-vessel stroke—but patients who did not receive IV clot-busting therapy showed better neurologic outcomes and a lower risk of brain bleeding.

Researchers say more studies are needed to confirm the findings. Read more here: https://hubs.li/Q03ZQJGC0

A recent trial reveals semaglutide's potential for neurological improvement in stroke patients, despite no overall functional recovery benefits.

01/08/2026

Infantile epileptic spasms are a neurologic emergency—early treatment can dramatically change a child’s future 🧠

At , pediatric epileptologists Dr. Christina Briscoe and Dr. Emily Spelbrink shared new research on why families from historically marginalized communities face delays in diagnosis and care—and what clinicians and systems can do differently.

Read more about the barriers, family perspectives, and paths toward equity here: https://hubs.li/Q03ZQwJN0

A pair of pediatric epileptologists highlight the systemic and patient level factors driving inequities in infantile epileptic spasms syndrome care and outline paths toward more equitable diagnosis and treatment.

01/06/2026

🧠✨ Action Update: December 2025

It was a busy month at the FDA! From new approvals and expanded indications to pivotal trial clearances and regulatory delays, December brought major updates across neurology—from narcolepsy and ALS to MS and myasthenia gravis. 💊📈

Catch up on all the key FDA decisions shaping the future of neurologic care and read more on NeurologyLive®: https://hubs.li/Q03ZDLV20

Catch up on any of the neurology news headlines you may have missed in December 2025, compiled into 1 place by the NeurologyLive® team.

01/06/2026

🧠🤖 AI is changing how we understand disability in MS

New research shows that people with multiple sclerosis who have the same EDSS score may experience very different types of disability—something traditional scoring doesn’t always capture.

Using artificial intelligence, researchers identified distinct patterns of functional impairment, offering a clearer picture of how MS affects daily life and how future treatments and trials could be improved 💡

👉 Read more to learn how AI could shape the future of MS care: https://hubs.li/Q03ZtCYY0

A new large-scale analysis revealed that patients with identical EDSS scores can exhibit distinct patterns of functional impairment, identified using artificial intelligence–based clustering algorithms.